Peptide substance restoring myocardium function — US7662789B2
Patent disclosure · 2010
- What the patent describes
- Cardiogen/AEDR animal and isolated-cardiomyocyte studies; no human cardiac-treatment cohort established in this patent review.
- Reported evidence
- Original patent behind the rat-infarction claim in the 2023 cardiovascular review. Kept separate from clinical evidence and peer-reviewed primary experiments.
Succinate-related respiration coefficient · 7.35 ± 0.26 in oxygen-deprived cells versus 1.97 ± 0.26 after peptide · Cellular respiration ratio; oxygen consumption in normally oxygenated cells was not altered
Reported patent results
Reported findings
The patent reports altered cellular respiration under oxygen deprivation and leukocyte changes in longer animal observations.
Cardiogen/AEDR animal and isolated-cardiomyocyte studies; no human cardiac-treatment cohort established in this patent review.
Population or model Cardiogen/AEDR animal and isolated-cardiomyocyte studies; no human cardiac-treatment cohort established in this patent review.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Succinate-related respiration coefficient | 7.35 ± 0.26 in oxygen-deprived cells versus 1.97 ± 0.26 after peptide | Cellular respiration ratio; oxygen consumption in normally oxygenated cells was not altered |
| Animal leukocytes | 11.2 ± 0.8 versus 9.4 ± 0.5 control at 3 months; 11.9 ± 0.5 versus 9.6 ± 0.5 at 6 months | ×10^9/L; 24 animals per displayed group · p<0.05 |
Cellular bioenergetics and animal blood counts do not establish improved cardiac outcomes in patients. A leukocyte change is not interchangeable with an absence of biological effects.
Source for these results ↗ · Reviewed 2026-11-06
Patent claims and provenance
Molecule. The claim concerns Ala-Glu-Asp-Arg (AEDR), the Cardiogen sequence; EP1758923 belongs to this family and is not the respiratory AEDL peptide.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- US7662789B2 ↗ · 2010-02-16
- Earliest priority / filing
- 2004-06-22 / 2004-12-07
- Original applicant / assignee
- Access Bioscience CJSC
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 34960195 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Peptide substance restoring myocardium function
Inventors: Vladimir Khatskelevich Khavinson; Galina Anatolievna Ryzhak; Evgeny Iosifovich Grigoriev; Irina Yurievna Ryadnova.
US7662789B2 · EP1758923B8 · ATE386047T1 · DE602004011843T2 · ES2302067T3 · RU2255756C1 · WO2006001728A1
Study limitations and source details
Study limitations
- Patent claims are not independent validation.
- No human cardiovascular benefit is established by this source.
Source details
Patent identity and its citation as reference 123 in the review checked; detailed experimental appraisal pending.
Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
Sources checked
Citation
V. Kh. Khavinson, G. A. Ryzhak, E. I. Grigoriev, I. Yu. Ryadnova. Peptide substance restoring myocardium function — US7662789B2 US patent 7,662,789 B2